AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films
Honeywell Aclar film technology will enable Evertis to develop high-quality barrier packaging solutions
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M
Rifaximin tablets had annual sales of US$ 2672.9 mn in the United States (IQVIA MAT March 2025)
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Subscribe To Our Newsletter & Stay Updated